Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NYSE MKT | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 22, 24 | -0.55 Decreased by -89.66% | -0.35 Decreased by -57.14% |
| Nov 14, 23 | -0.75 Decreased by -212.5% | -0.31 Decreased by -141.94% |
| Aug 14, 23 | -0.1 Increased by +61.54% | -0.37 Increased by +72.97% |
| May 11, 23 | -0.4 Decreased by -33.33% | -0.32 Decreased by -25% |
| Mar 16, 23 | -0.29 Decreased by -26.09% | -0.28 Decreased by -3.57% |
| Nov 9, 22 | -0.24 Decreased by -9.09% | -0.28 Increased by +14.29% |
| Aug 11, 22 | -0.26 Decreased by -4% | -0.23 Decreased by -13.04% |
| May 12, 22 | -0.3 Decreased by -11.11% | -0.21 Decreased by -42.86% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | N/A Decreased by -100% | -19.85 M Decreased by -92.67% | - - |
| Sep 30, 23 | 1.23 M Decreased by -8.45% | -31.16 M Decreased by -262.13% | Decreased by -2.54 K% Decreased by -295.53% |
| Jun 30, 23 | 980 K Increased by +N/A% | -3.55 M Increased by +61.49% | Decreased by -361.94% Decreased by N/A% |
| Mar 31, 23 | 796 K Increased by +N/A% | -17.63 M Decreased by -101% | Decreased by -2.22 K% Decreased by N/A% |
| Dec 31, 22 | 1.05 M Increased by +49.06 K% | -10.3 M Decreased by -70.35% | Decreased by -980.11% Increased by +99.65% |
| Sep 30, 22 | 1.34 M Increased by +106.85 K% | -8.61 M Decreased by -58.79% | Decreased by -643.12% Increased by +99.85% |
| Jun 30, 22 | 0 Decreased by -100% | -9.21 M Decreased by -48.69% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by -100% | -8.77 M Decreased by -59.65% | Decreased by N/A% Decreased by N/A% |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.